HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 1, 2015, Pages 66-75

  Haj, Christeene G ^a   Sumariwalla, Percy F ^b   Hanuš, Lumír ^a   Kogan, Natalya M ^a   Yektin, Zhana ^a   Mechoulam, Raphael ^a   Feldmann, Mark ^b   Gallily, Ruth ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8,9 DIHYDRO CANNABIDIOL 7 OIC ACID DIACETATE; ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ASPARTATE AMINOTRANSFERASE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; CANNABIDIOL; CANNABINOID RECEPTOR; CONCANAVALIN A; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; HU-444;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; ANIMAL; ARTHRITIS, EXPERIMENTAL; BIOSYNTHESIS; CELL PROTECTION; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; INJURIES; LIVER; MACROPHAGE; METABOLISM;

ACETATES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CANNABIDIOL; CONCANAVALIN A; CYCLOHEXANECARBOXYLIC ACIDS; CYTOPROTECTION; FEMALE; LIVER; MACROPHAGES; MALE; MICE; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; RECEPTORS, CANNABINOID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941695739     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.226100     Document Type: Article

References (55)

1. Avraham Y, Grigoriadis N, Poutahidis T, Vorobiev L, Magen I, Ilan Y, Mechoulam R, and Berry E (2011) Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol 162:1650-1658.
2. Bayewitch M, Rhee MH, Avidor-Reiss T, Breuer A, Mechoulam R, and Vogel Z (1996) (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptormediated inhibition of adenylyl cyclase. J Biol Chem 271:9902-9905.
3. Ben-Shabat S, Hanus LO, Katzavian G, and Gallily R (2006) New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 49:1113-1117.
4. Bergamaschi MM, Queiroz RH, Chagas MH, De Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, and Nardi AE, et al. (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36:1219-1226.
5. Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, and Sala M (2003) Postishemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 346:61-64.
6. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, and Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35:3135-3141.
7. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, and Mechoulam R (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175-185.
8. Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, and Mechoulam R (1992a) A novel probe for the cannabinoid receptor. J Med Chem 35:2065-2069.
9. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992b) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
10. Durst R, Danenberg H, Gallily R, Mechoulam R, Meir K, Grad E, Beeri R, Pugatsch T, Tarsish E, and Lotan C (2007) Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol 293:H3602-H3607.
11. Feldmann M, Brennan FM, Elliott MJ, Williams RO, and Maini RN (1995) TNF alpha is an effective therapeutic target for rheumatoid arthritis. Ann N YAcad Sci 766:272-278.
12. Feldmann M, Williams RO, and Paleolog E (2010) What have we learnt from targeted anti-TNF therapy? Ann Rheum Dis 69(Suppl 1):i97-i99.
13. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, and Martínez-Orgado J (2013) Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 75:323-333.
14. Fride E and Mechoulam R (1993) Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231:313-314.
15. Full LE, Ruisanchez C, and Monaco C (2009) The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 11:217-227.
16. Gaoni Y and Mechoulam R (1971 The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 93:217-224.
17. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, and Axelrod J (2000) Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 899:274-282.
18. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M, Orito K, Abe K, Hasebe N, and Egashira N, et al. (2007) Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem 102:1488-1496.
19. Holum JR (1961) Study of the chromium (VI) oxide-pyridine complex. J Org Chem 26:4814-4816.
20. Jamontt JM, Molleman A, Pertwee RG, and Parsons ME (2010) The effects of D-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160:712-723.
21. Kozela E, Haj C, Hanus L, Chourasia M, Shurki A, Juknat A, Kaushansky N, Mechoulam R, and Vogel Z (2015) HU-446 and HU-465, derivatives of the nonpsychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. Chem Biol Drug Des, in press.
22. Krawitt EL (2006) Autoimmune hepatitis. N Engl J Med 354:54-66.
23. Küsters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Künstle G, Bluethmann H, Wendel A, Pfizenmaier K, and Kollias G, et al. (1997) In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27:2870-2875.
24. Lander N, Ben-Zvi Z, Mechoulam R, Martin B, Nordqvist M, and Agurell S (1976) Total synthesis of cannabidiol and A1-THC metabolites. J Chem Soc Perkin Trans 1:8-16.
25. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, and Fernández-Ruiz J (2005) Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19:96-107.
26. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, and Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94.
27. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, and Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97:9561-9566.
28. Marmor JB (1998) Medical marijuana. West J Med 168:540-543.
29. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, and Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
30. Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, and De Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 79:964-973.
31. Massi P, Solinas M, Cinquina V, and Parolaro D (2013) Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 75:303-312.
32. Mechoulam R, Hanus LO, Pertwee R, and Howlett AC (2014) Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci 15:757-764.
33. Mechoulam R, Parker LA, and Gallily R (2002) Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42:11S-19S.
34. Mechoulam R, Peters M, Murillo-Rodriguez E, and Hanus LO (2007) Cannabidiol: recent advances. Chem Biodivers 4:1678-1692.
35. Mechoulam R, Sumariwalla PF, Feldmann M, and Gallily R (2005) Cannabinoids in models of chronic inflammatory conditions. Phytochem Rev 4:11-18.
36. Ohta A and Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-920.
37. Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, and Martínez-Orgado J (2012) Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63:776-783.
38. Pellegata R, Ventura P, Villa M, Palmisano G, and Lesma G (1986) An improved procedure for the synthesis of oleuropeic acid. Synth Commun 15:165-170.
39. Pertwee RG (2005) Pharmacological actions of cannabinoids. Handbook Exp Pharmacol 168:1-51.
40. Porter BE and Jacobson C (2013) Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29:574-577.
41. Ratcliffe R and Rodehorst R (1970) Improved procedure for oxidations with the chromium trioxide-pyridine complex. J Org Chem 35:4000-4002.
42. Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, and Parker LA (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT (1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165:2620-2634.
43. Sharpless KB and Lauer RF (1972) Selenium dioxide oxidation of olefins: evidence for the intermediacy of allylselenic acids. J Am Chem Soc 94:7154-7155.
44. Stephenson LM and Speth DR (1979) Mechanism of allylic hydroxylation by selenium dioxide. J Org Chem 44:4683-4689.
45. Sumariwalla PF, Cao Y, Wu HL, Feldmann M, and Paleolog EM (2003) The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res Ther 5:R32-R39.
46. Sumariwalla PF, Gallily R, Tchilibon S, Fride E, Mechoulam R, and Feldmann M (2004) A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 50:985-998.
47. Syed YY, McKeage K, and Scott LJ (2014) Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs 74:563-578.
48. Taylor PC, Williams RO, and Maini RN (2001) Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 13:611-616.
49. Tiegs G, Hentschel J, and Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90:196-203.
50. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, and Gallily R (2008) Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54:244-249.
51. Williams RO (1998) Rodent models of arthritis: relevance for human disease. Clin Exp Immunol 114:330-332.
52. Williams RO (2004) Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med 98:207-216.
53. Williams RO (2007) Collagen-induced arthritis in mice. Methods Mol Med 136:191-199.
54. Zhornitsky S and Potvin S (2012) Cannabidiol in humans: the quest for therapeutic targets. Pharmaceuticals (Basel) 5:529-552.
55. Zurier RB (2003) Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 88:462-466.